fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

First randomised trial finds AI-supported mammography screening is safe and almost halved radiologist workload

Written by | 3 Aug 2023

An interim safety analysis of the first randomised controlled trial of its kind involving over 80,000 Swedish women published in The Lancet Oncology journal, finds artificial intelligence (AI)-supported mammography analysis… read more.

The largest study of its kind shows a need for improvement in esophageal cancer screenings

Written by | 25 Jul 2023

A new study published in Gastroenterology aims to improve the effectiveness of screening and surveillance practices for early cancer detection in Barrett’s esophagus (BE). BE is the only identifiable precursor… read more.

European Commission grants conditional approval for Lytgobi to treat cholangiocarcinoma – Taiho Oncology Europe

Written by | 21 Jul 2023

Taiho Pharmaceutical and its subsidiary Taiho Oncology Europe have received conditional marketing authorisation from the European Commission for Lytgobi (futibatinib) tablets to treat adults with cholangiocarcinoma (CCA). The… read more.

Curettage and cryosurgery – effective for the most common skin cancer

Written by | 16 Jul 2023

The combination of curettage and cryosurgery is a safe and effective treatment method for the most common form of skin cancer, basal cell carcinoma. A study from the… read more.

European Commission approves Opdivo + chemotherapy for neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients with tumor cell PD-L1 expression greater than 1% – BMS

Written by | 16 Jul 2023

Bristol Myers Squibb announced that the European Commission (EC) has approved Opdivo (nivolumab) in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small cell lung cancer… read more.

Efficacy of fruquintinib confirmed in refractory metastatic colorectal cancer

Written by | 19 Jun 2023

In patients with refractory metastatic colorectal cancer, fruquintinib treatment has resulted in a significant improvement in overall survival compared with placebo. Researchers reported this finding on June 15,… read more.

Survival benefit from frontline immunotherapy in progression-free non–small cell lung cancer peaks at 2 years

Written by | 13 Jun 2023

For patients who are progression-free after two years of frontline immunotherapy for advanced non–small cell lung cancer (NSCLC), there does not appear to be a survival benefit in… read more.

Presentation of longer-term data for Tecvayli showing a duration of response of 22 months in patients with r/r multiple myeloma – Janssen

Written by | 12 Jun 2023

The Janssen Pharmaceutical Companies of Johnson & Johnson announced long-term data from the pivotal Phase 1/II MajesTEC-1 study showing the sustained efficacy and safety of Tecvayli (teclistamab-cqyv) in… read more.

Targeted therapy for brain cancer shows efficacy

Written by | 10 Jun 2023

In patients diagnosed with grade 2 IDH-mutant glioma, treatment with investigative vorasidenib has significantly improved progression-free survival. The findings were published on June 5, 2023 in the NEJM/New… read more.

New drug delays progression of glioma, a deadly brain cancer

Written by | 7 Jun 2023

In an international study co-led by UCLA, scientists have shown that a new targeted therapy drug can extend the amount of time people with a subtype of glioma… read more.

Keytruda + chemotherapy before surgery and continued as a single agent after surgery reduced the risk of event-free survival events by 42% versus pre-operative chemotherapy in resectable Stage II, IIIA or IIIB NSCLC – Merck Inc

Written by | 7 Jun 2023

Merck known as MSD outside of the United States and Canada, announced positive results from the pivotal Phase III KEYNOTE-671 trial evaluating Keytruda, Merck’s anti-PD-1 therapy, as a… read more.

Could pharmacist-prescribing reduce chemotherapy errors?

Written by | 24 May 2023

Shannon Nally is a pharmacist with a strong background in aseptic pharmacy work and oncology. Whilst studying for a master’s degree at University College Cork (UCC) she undertook… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.